Trial Profile
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Periampullary cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors BIND Therapeutics
- 04 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 09 Nov 2015 Results (n=28), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
- 09 Nov 2015 Results of pooled analysis from this and other two phase II trials (n=110), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.